Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.282
-0.008 (-2.76%)
Nov 15, 2024, 4:00 PM EST
Northwest Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1.6 | 1.93 | 1.68 | 1.01 | 1.29 | 2.41 | Upgrade
|
| Revenue Growth (YoY) | -23.42% | 14.80% | 67.46% | -22.15% | -46.43% | 484.95% | Upgrade
|
| Cost of Revenue | 27.73 | 27.73 | 35.51 | 20.31 | 33.64 | 14.11 | Upgrade
|
| Gross Profit | -26.13 | -25.8 | -33.83 | -19.3 | -32.35 | -11.7 | Upgrade
|
| Selling, General & Admin | 32.93 | 29.71 | 33.35 | 33.4 | 54.26 | 16.28 | Upgrade
|
| Operating Expenses | 37.02 | 29.71 | 33.35 | 33.4 | 54.26 | 16.28 | Upgrade
|
| Operating Income | -63.15 | -55.51 | -67.18 | -52.7 | -86.61 | -27.98 | Upgrade
|
| Interest Expense | -6.52 | -5.24 | -6.07 | -5.01 | -8.54 | -2.98 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.13 | 2.01 | -3.3 | -1.7 | 2.26 | 0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.67 | 1.55 | -25.79 | 238.7 | -435.35 | 11.83 | Upgrade
|
| EBT Excluding Unusual Items | -57.87 | -57.2 | -102.34 | 179.29 | -528.24 | -18.87 | Upgrade
|
| Other Unusual Items | -11.66 | -5.4 | -2.69 | -0.17 | -1.58 | -1.94 | Upgrade
|
| Pretax Income | -69.53 | -62.6 | -105.03 | 179.13 | -529.82 | -20.81 | Upgrade
|
| Net Income | -69.53 | -62.6 | -105.03 | 179.13 | -529.82 | -20.81 | Upgrade
|
| Preferred Dividends & Other Adjustments | 1.48 | 1.77 | - | - | - | - | Upgrade
|
| Net Income to Common | -71.01 | -64.37 | -105.03 | 179.13 | -529.82 | -20.81 | Upgrade
|
| Shares Outstanding (Basic) | 1,205 | 1,119 | 1,016 | 874 | 725 | 564 | Upgrade
|
| Shares Outstanding (Diluted) | 1,205 | 1,119 | 1,016 | 1,008 | 725 | 564 | Upgrade
|
| Shares Change (YoY) | 10.13% | 10.17% | 0.79% | 38.99% | 28.53% | 28.22% | Upgrade
|
| EPS (Basic) | -0.06 | -0.06 | -0.10 | 0.21 | -0.73 | -0.04 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.06 | -0.10 | -0.06 | -0.73 | -0.04 | Upgrade
|
| Free Cash Flow | -55.15 | -57.07 | -55.68 | -44.31 | -38.7 | -32.22 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.06 | Upgrade
|
| Operating Margin | -3956.83% | -2873.08% | -3991.74% | -5243.98% | -6708.37% | -1160.95% | Upgrade
|
| Profit Margin | -4449.50% | -3331.94% | -6240.76% | 17823.48% | -41039.58% | -863.57% | Upgrade
|
| Free Cash Flow Margin | -3455.39% | -2954.14% | -3308.20% | -4409.35% | -2997.91% | -1336.89% | Upgrade
|
| EBITDA | -61.42 | -53.98 | -65.93 | -52.38 | -86.52 | -27.96 | Upgrade
|
| D&A For EBITDA | 1.73 | 1.53 | 1.25 | 0.32 | 0.09 | 0.02 | Upgrade
|
| EBIT | -63.15 | -55.51 | -67.18 | -52.7 | -86.61 | -27.98 | Upgrade
|
| Revenue as Reported | 1.6 | 1.93 | 1.68 | 1.01 | 1.29 | 2.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.